¼¼°èÀÇ ±Þ¼º ¸²ÇÁ¼º/¸²ÇÁ¸ð±¸¼º ¹éÇ÷º´ Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Çâ, ¾÷°è ºÐ¼® : Á¦Ç°º°, ¿ëµµº°, ¼ºº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº° - ½ÃÀå ¿¹Ãø(2025-2034³â)
Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Product, Application, Gender, End Use, and Region - Market Forecast, 2025-2034
»óǰÄÚµå : 1671156
¸®¼­Ä¡»ç : Polaris Market Research
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 117 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,250 £Ü 6,149,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,250 £Ü 7,596,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ 20¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,250 £Ü 9,043,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Polaris Market ResearchÀÇ ÃֽŠÁ¶»ç¿¡ µû¸£¸é, ±Þ¼º ¸²ÇÁ¼º/¸²ÇÁ¸ð±¸¼º ¹éÇ÷º´ Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð´Â 2034³â±îÁö 69¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ º¸°í¼­´Â ÇöÀç ½ÃÀå ¿ªÇп¡ ´ëÇÑ ÀÚ¼¼ÇÑ ÀλçÀÌÆ®¿Í ÇâÈÄ ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

±Þ¼º ¸²ÇÁ¼º/¸²ÇÁ¸ð±¸¼º ¹éÇ÷º´(ALL) Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀº ÀÌ ÁúȯÀÇ À¯º´·ü Áõ°¡, Ä¡·á ¿É¼ÇÀÇ ¹ßÀü, Á¶±â Áø´Ü¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡ µî ¿©·¯ °¡Áö ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. ¸é¿ª¿ä¹ý, ƯÈ÷ Ű¸Þ¶ó Ç׿ø ¼ö¿ëü(CAR) T ¼¼Æ÷ Ä¡·áÀÇ ºÎ»óÀº Àç¹ß¼º ¶Ç´Â ºÒÀÀ¼º ALL ȯÀÚ¿¡°Ô »õ·Î¿î Èñ¸ÁÀ» °¡Á®´Ù ÁÖ¾úÀ¸¸ç, Ç¥Àû Ä¡·á´Â Çʶóµ¨ÇÇ¾Æ ¿°»öü ¾ç¼º ALL°ú °°Àº À¯ÀüÀûÀ¸·Î Á¤ÀÇµÈ ¾ÆÇü¿¡ ´ëÇÑ Ä¡·á °á°ú¸¦ °³¼±Çϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ, À¯ÀüÀÚ ¹× ºÐÀÚ ÇÁ·ÎÆÄÀϸµ¿¡ ±â¹ÝÇÏ¿© Ä¡·á µ¿ÇâÀ» Á¶Á¤ÇÏ´Â Á¤¹ÐÀÇ·á·ÎÀÇ ÀüȯÀÌ ÀÌ ½ÃÀåÀÇ Áß¿äÇÑ Æ®·»µåÀÔ´Ï´Ù. ±Þ¼º ¸²ÇÁ¼º/¸²ÇÁ¸ð±¸¼º ¹éÇ÷º´ Ä¡·áÁ¦ÀÇ ½ÃÀå ±âȸ´Â ÀÇ·á Á¢±Ù¼ºÀÌ °³¼±µÇ°í È¿´ÉÀ» ³ôÀ̱â À§ÇÑ º´¿ë¿ä¹ý¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¿¬±¸¿Í ÇÔ²² ÀÇ·á Á¢±Ù¼ºÀÌ °³¼±µÊ¿¡ µû¶ó Ä¡·á Á¢±Ù¼ºÀÌ ³·Àº Áö¿ª¿¡¼­µµ »ý°Ü³ª°í ÀÖ½À´Ï´Ù.

±Þ¼º ¸²ÇÁ¼º/¸²ÇÁ¸ð±¸¼º ¹éÇ÷º´ Ä¡·áÁ¦ ½ÃÀå : ºÐ¼® °³¿ä

Á¦Ç°º°·Î´Â È­Çпä¹ý ºÐ¾ß°¡ ±Þ¼º ¸²ÇÁ¼º/¸²ÇÁ¸ð±¸¼º ¹éÇ÷º´ Ä¡·áÁ¦ ½ÃÀå ¸ÅÃâ¿¡¼­ °¡Àå Å« ºñÁßÀ» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. È­Çпä¹ýÀº ALLÀÇ Ç¥ÁØÄ¡·á·Î ¿©°ÜÁö°í ÀÖ½À´Ï´Ù. ±×·¯³ª Ç¥Àû Ä¡·áÁ¦ ºÐ¾ß´Â Ƽ·Î½ÅŰ³ª¾ÆÁ¦ ¾ïÁ¦Á¦, CAR T ¼¼Æ÷ Ä¡·áÁ¦ µîÀÇ ±â¼ú Çõ½Å¿¡ ÈûÀÔ¾î °¡Àå ºü¸£°Ô ¼ºÀåÇϰí ÀÖ´Â ºÐ¾ßÀÔ´Ï´Ù.

Àü±¸ B¼¼Æ÷¼º ALLÀº ³ôÀº À¯º´·ü·Î ÀÎÇØ ¿ëµµº°·Î´Â Àü±¸ B¼¼Æ÷¼º ALLÀÌ Áö¹èÀûÀÎ ºÎ¹®ÀÔ´Ï´Ù. ¹Ý¸é, Çʶóµ¨ÇÇ¾Æ ¿°»öü ¾ç¼º ALL ºÎ¹®Àº Ç¥Àû Ä¡·áÁ¦ »ç¿ë Áõ°¡¿¡ ÈûÀÔ¾î °¡Àå ³ôÀº ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù.

¼ºº°·Î´Â ³²¼ºÀÌ ALL Áø´ÜÀ» ¹Þ´Â ºóµµ°¡ ³ô±â ¶§¹®¿¡ ³²¼º ºÎ¹®ÀÇ ½ÃÀå Á¡À¯À²ÀÌ ³ôÁö¸¸, ¿©¼º ºÎ¹®Àº Á¶±â Áø´ÜÀÇ Áõ°¡¿Í Ä¡·á ¼º°úÀÇ °³¼±À¸·Î ³ôÀº ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù.

ÃÖÁ¾»ç¿ëÀÚº°·Î´Â º´¿ø ¹× Ŭ¸®´ÐÀÌ ´Ù¾çÇÑ Ä¡·á¹ýÀ» Á¦°øÇÔ¿¡ µû¶ó ±Þ¼º ¸²ÇÁ¼º/¸²ÇÁ¸ð±¸¼º ¹éÇ÷º´ Ä¡·áÁ¦ ½ÃÀå Á¡À¯À²À» µ¶½ÄÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ¸é¿ª¿ä¹ý, Áٱ⼼Æ÷ ÀÌ½Ä µî °íµµÀÇ Á¾¾çÇÐ Ä¡·á¿¡ ƯȭµÇ¾î ÀÖ¾î ¾Ï Ä¡·á ¼¾ÅͰ¡ °¡Àå ºü¸£°Ô ¼ºÀåÇϰí ÀÖ½À´Ï´Ù.

ºÏ¹Ì´Â ³ôÀº ÀÇ·á ÀÎÇÁ¶ó¿Í ³ôÀº Ä¡·á µµÀÔ·ü·Î ¼¼°è ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖÁö¸¸, ¾Æ½Ã¾ÆÅÂÆò¾çÀº ÀÇ·á Á¢±Ù¼º È®´ë¿Í ÷´Ü Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ °¡Àå ³ôÀº ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼Ò°³

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ºÐ¼® ¹æ¹ý

Á¦4Àå ±Þ¼º ¸²ÇÁ¼º/¸²ÇÁ¸ð±¸¼º ¹éÇ÷º´ Ä¡·áÁ¦ ½ÃÀå ÀλçÀÌÆ®

Á¦5Àå ¼¼°èÀÇ ±Þ¼º ¸²ÇÁ¼º/¸²ÇÁ¸ð±¸¼º ¹éÇ÷º´ Ä¡·áÁ¦ ½ÃÀå : ¿ëµµº°

Á¦6Àå ¼¼°èÀÇ ±Þ¼º ¸²ÇÁ¼º/¸²ÇÁ¸ð±¸¼º ¹éÇ÷º´ Ä¡·áÁ¦ ½ÃÀå : Á¦Ç°º°

Á¦7Àå ¼¼°èÀÇ ±Þ¼º ¸²ÇÁ¼º/¸²ÇÁ¸ð±¸¼º ¹éÇ÷º´ Ä¡·áÁ¦ ½ÃÀå : ¼ºº°

Á¦8Àå ¼¼°èÀÇ ±Þ¼º ¸²ÇÁ¼º/¸²ÇÁ¸ð±¸¼º ¹éÇ÷º´ Ä¡·áÁ¦ ½ÃÀå : ÃÖÁ¾ ¿ëµµº°

Á¦9Àå ¼¼°èÀÇ ±Þ¼º ¸²ÇÁ¼º/¸²ÇÁ¸ð±¸¼º ¹éÇ÷º´ Ä¡·áÁ¦ ½ÃÀå : Áö¿ªº°

Á¦10Àå °æÀï ±¸µµ

Á¦11Àå ±â¾÷ °³¿ä

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The acute lymphocytic/lymphoblastic leukemia therapeutics market size is expected to reach USD 6.97 billion by 2034, according to a new study by Polaris Market Research. The report "Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Size, Share, Trends, Industry Analysis Report: By Product (Chemotherapy, Targeted Therapy, Radiation Therapy, and Stem Cell Transplantation), Application, Gender, End Use, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The acute lymphocytic/lymphoblastic leukemia (ALL) therapeutics market growth is driven by several factors such as the increasing prevalence of the disease, advancements in treatment options, and growing awareness about early diagnosis. The rise of immunotherapies, particularly chimeric antigen receptor (CAR) T-cell therapies, offers new hope for patients suffering from relapsed or refractory ALL, while targeted therapies are improving outcomes for genetically defined subtypes such as Philadelphia chromosome-positive ALL.

Additionally, the shift toward precision medicine, where treatments are tailored based on genetic and molecular profiling, is a key trend in the market. Acute lymphocytic/lymphoblastic leukemia therapeutics market opportunities are also emerging in underserved regions as healthcare access improves, alongside ongoing research into combination therapies to enhance effectiveness.

Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Report Highlights

Based on product, the chemotherapy segment holds the largest share of the acute lymphocytic/lymphoblastic leukemia therapeutics market revenue. Chemotherapy is considered a standard treatment for ALL. However, the targeted therapy segment is the fastest-growing segment, driven by innovations such as tyrosine kinase inhibitors and CAR T-cell therapies.

Precursor B-cell ALL is the dominant segment, based on application, due to its high prevalence. On the other side, the Philadelphia chromosome-positive ALL segment is experiencing the highest growth, fueled by the increased use of targeted therapies.

The male segment, based on gender, holds a larger market share, as males are more frequently diagnosed with ALL, while the female segment is showing a higher growth, with increasing early diagnosis and improved treatment outcomes.

In terms of end use, the hospitals and clinics segment dominate the acute lymphocytic/lymphoblastic leukemia therapeutics market share, as it offers a broad range of treatments. However, cancer care centers are the fastest growing due to their specialized focus on advanced oncology therapies such as immunotherapies and stem cell transplants.

North America dominates the global market due to advanced healthcare infrastructure and high treatment adoption rates, while Asia Pacific is the highest growing, driven by expanding healthcare access and rising demand for advanced therapies.

Polaris Market Research has segmented the acute lymphocytic/lymphoblastic leukemia therapeutics market report on the basis of product, application, gender, end use, and region:

By Product Outlook (Revenue - USD Billion, 2020-2034)

By Application Outlook (Revenue - USD Billion, 2020-2034)

By Gender Outlook (Revenue - USD Billion, 2020-2034)

By End Use Outlook (Revenue - USD Billion, 2020-2034)

By Regional Outlook (Revenue - USD Billion, 2020-2034)

Table of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Insights

5. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Application

6. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Product

7. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Gender

8. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by End-use

9. Global Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market, by Geography

10. Competitive Landscape

11. Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â